We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hemostatic and Anti-Inflammatory Effects of Ulinastatin and Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2015 by SHI Jia, Cardiovascular Institute & Fuwai Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01060189
First Posted: February 2, 2010
Last Update Posted: April 13, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
SHI Jia, Cardiovascular Institute & Fuwai Hospital
  Purpose
Antifibrinolytic drugs are used to decrease perioperative bleeding and allogeneic transfusions. The extensively studied antifibrinolytic drug aprotinin is efficacious but expensive, and has been proved to link to higher risks of serious side effects including renal problems, myocardial events, and strokes in patients undergoing CABG. After the secession of aprotinin in 2007, a marked increase of blood loss and transfusions in cardiac surgery took place. An effective and secure hemostatic agent is badly needed. Ulinastatin, urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor with a wide inhibition spectrum, including plasmin. Limited studies offered clues to its antifibrinolytic effect. Tranexamic acid has been applied for years with convinced efficacy and safety. The objective of the study is to evaluate the hemostatic and anti-inflammatory effect of ulinastatin and tranexamic acid in cardiac surgery.

Condition Intervention
Hemostasis Drug: UTI & TA

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Hemostatic and Anti-Inflammatory Effects of Ulinastatin and Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery

Resource links provided by NLM:


Further study details as provided by SHI Jia, Cardiovascular Institute & Fuwai Hospital:

Primary Outcome Measures:
  • Postoperative blood loss(chest drainage) [ Time Frame: on the 30th day postoperatively ]
  • Perioperative allogeneic transfusions [ Time Frame: on the 30th day postoperatively ]

Secondary Outcome Measures:
  • Rate of reexploration for bleeding [ Time Frame: on the 30th day postoperatively ]
  • Length of stay in ICU and hospital postoperatively [ Time Frame: on the 30th day postoperatively ]
  • Coagulatory and fibrinolytic status [ Time Frame: 6hrs, 12hrs and 24hrs postoperatively ]
  • Inflammatory cytokines [ Time Frame: 6hrs, 12hrs and 24hrs postoperatively ]

Estimated Enrollment: 350
Study Start Date: February 2010
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ulinastatin
1,000,000 units after anesthetic induction 1,000,000 units after heparinization 1,000,000 units after neutralization
Drug: UTI & TA
Ulinastatin, tranexamic acid and the combination of the two
Experimental: Tranexamic Acid
15mg after heparinization 15mg after neutralization
Drug: UTI & TA
Ulinastatin, tranexamic acid and the combination of the two
Experimental: Combination

Ulinastatin 1,000,000 units after anesthetic induction 1,000,000 units after heparinization 1,000,000 units after neutralization

Tranexamic Acid 15mg after heparinization 15mg after neutralization

Drug: UTI & TA
Ulinastatin, tranexamic acid and the combination of the two
Placebo Comparator: Placebo
saline solution 50ml after anesthetic induction 50ml after heparinization 50ml after neutralization
Drug: UTI & TA
Ulinastatin, tranexamic acid and the combination of the two

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Atrial or ventricular septum defect patients requiring cardiac surgery with CPB
  • Rheumatic or recessive valvular patients requiring valvular repair or replacement with CPB
  • Coronary artery disease patients requiring coronary revascularization with CPB

Exclusion Criteria:

  • Non-primary cardiac surgery
  • Definite liver and renal dysfunction
  • Disorder in coagulation function
  • Allergy
  • Pregnancy and lactation
  • Disabled in spirit or law
  • Fatal conditions such as tumour
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01060189


Contacts
Contact: Lihuan Li, MD 86-10-88398184 llhfw@sina.com
Contact: Jia Shi, MD 86-10-88398082 shiandypumc@sina.com

Locations
China, Beijing
Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC Recruiting
Beijing, Beijing, China, 100037
Contact: Lihuan Li, MD    86-10-88398184    llhfw@sina.com   
Contact: Jia Shi, MD    86-10-88398082    shiandypumc@sina.com   
Principal Investigator: Lihuan Li, MD         
Sub-Investigator: Jia Shi, MD         
Sponsors and Collaborators
Chinese Academy of Medical Sciences, Fuwai Hospital
Investigators
Study Chair: Lihuan Li, MD Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC
Principal Investigator: Jia Shi, MD Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC
  More Information

Responsible Party: SHI Jia, Attending doctor of the department of anesthesiology and critical care, Fuwai Hospital, NCCD, PUMC & CAMS, Cardiovascular Institute & Fuwai Hospital
ClinicalTrials.gov Identifier: NCT01060189     History of Changes
Other Study ID Numbers: UTI Trial China
First Submitted: January 28, 2010
First Posted: February 2, 2010
Last Update Posted: April 13, 2015
Last Verified: April 2015

Keywords provided by SHI Jia, Cardiovascular Institute & Fuwai Hospital:
ulinastatin
tranexamic acid
cardiac surgery procedures
hemostasis
anti-inflammation

Additional relevant MeSH terms:
Tranexamic Acid
Hemostatics
Anti-Inflammatory Agents
Urinastatin
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Coagulants
Trypsin Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors